CN118647378A - 梅嫩蛋白与mll相互作用的抑制剂 - Google Patents

梅嫩蛋白与mll相互作用的抑制剂 Download PDF

Info

Publication number
CN118647378A
CN118647378A CN202280090933.7A CN202280090933A CN118647378A CN 118647378 A CN118647378 A CN 118647378A CN 202280090933 A CN202280090933 A CN 202280090933A CN 118647378 A CN118647378 A CN 118647378A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
formula
solvate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280090933.7A
Other languages
English (en)
Chinese (zh)
Inventor
鲁本·阿巴扬
弗拉迪斯拉夫·泽诺诺维奇·帕钦斯基
尼古拉·萨楚克
亚历山大·瓦西里耶维奇·伊瓦奇琴科
亚历山大·库瓦特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bala Therapy Co
Original Assignee
Bala Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bala Therapy Co filed Critical Bala Therapy Co
Publication of CN118647378A publication Critical patent/CN118647378A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202280090933.7A 2021-12-09 2022-12-09 梅嫩蛋白与mll相互作用的抑制剂 Pending CN118647378A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163287716P 2021-12-09 2021-12-09
US63/287,716 2021-12-09
US202263306399P 2022-02-03 2022-02-03
US63/306,399 2022-02-03
US202263397322P 2022-08-11 2022-08-11
US63/397,322 2022-08-11
PCT/US2022/052404 WO2023107696A2 (en) 2021-12-09 2022-12-09 Inhibitors of menin-mll interaction

Publications (1)

Publication Number Publication Date
CN118647378A true CN118647378A (zh) 2024-09-13

Family

ID=86731242

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280090933.7A Pending CN118647378A (zh) 2021-12-09 2022-12-09 梅嫩蛋白与mll相互作用的抑制剂

Country Status (11)

Country Link
US (2) US20250163061A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444300A4 (cg-RX-API-DMAC7.html)
JP (2) JP2024545184A (cg-RX-API-DMAC7.html)
KR (2) KR20240117133A (cg-RX-API-DMAC7.html)
CN (1) CN118647378A (cg-RX-API-DMAC7.html)
AU (2) AU2022405438A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240074A1 (cg-RX-API-DMAC7.html)
JO (1) JOP20240130A1 (cg-RX-API-DMAC7.html)
MX (2) MX2024007069A (cg-RX-API-DMAC7.html)
TW (1) TW202529770A (cg-RX-API-DMAC7.html)
WO (1) WO2023107696A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202529770A (zh) * 2021-12-09 2025-08-01 美商巴拉療法公司 梅嫩蛋白（ｍｅｎｉｎ）－ＭＬＬ相互作用之抑制劑

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016197027A1 (en) * 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
BR112018012707A2 (pt) * 2015-12-22 2019-01-29 Vitae Pharmaceuticals Inc inibidores da interação de menin-mll
TW201920170A (zh) * 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
TW202529770A (zh) * 2021-12-09 2025-08-01 美商巴拉療法公司 梅嫩蛋白（ｍｅｎｉｎ）－ＭＬＬ相互作用之抑制劑

Also Published As

Publication number Publication date
JP2024545184A (ja) 2024-12-05
JOP20240130A1 (ar) 2024-06-10
US20260022120A1 (en) 2026-01-22
CA3240074A1 (en) 2023-06-15
US20250163061A1 (en) 2025-05-22
KR20250135350A (ko) 2025-09-12
WO2023107696A3 (en) 2023-07-27
AU2022405438A1 (en) 2024-06-20
AU2025230651A1 (en) 2025-09-25
EP4444300A4 (en) 2026-03-18
MX2024007069A (es) 2024-08-22
TW202529770A (zh) 2025-08-01
JP2025170331A (ja) 2025-11-18
MX2025012108A (es) 2025-11-03
KR20240117133A (ko) 2024-07-31
WO2023107696A2 (en) 2023-06-15
EP4444300A2 (en) 2024-10-16
TW202337435A (zh) 2023-10-01

Similar Documents

Publication Publication Date Title
AU2022200741B2 (en) Aminothiazole compounds as c-Kit inhibitors
CN115956075B (zh) 用于治疗与pi3k调节相关的疾病的磷酸肌醇3-激酶(pi3k)的变构色烯酮抑制剂
CN101356172B (zh) 激酶抑制剂
CN109983001B (zh) 作为变构shp2抑制剂的2,5-双取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪
CN107873031B (zh) 作为tnf活性调节剂的苯并噁嗪酮衍生物及其类似物
CN110431134A (zh) 作为变构shp2抑制剂的吡啶化合物
CN110446709A (zh) 作为变构shp2抑制剂的二环化合物
CN112969694B (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其用途
TW201831481A (zh) 作為Ｒｈｏ激酶抑制劑之酪胺酸醯胺衍生物
TW201512173A (zh) 炔基醇及其使用方法
WO2015165341A1 (zh) 作为rho激酶抑制剂的异喹啉磺酰衍生物
CN107108641A (zh) 大环lrrk2激酶抑制剂
CN115867346A (zh) 激酶抑制剂
CN119522216A (zh) Ptpn2抑制剂
CN110099906A (zh) 作为激酶抑制剂的酰胺化合物
TW202339722A (zh) Ｌｒｒｋ２抑制劑
JP2024539633A (ja) 置換１Ｈ－ピラゾロ［４，３－ｃ］キノリン、その調製方法、および使用
JP2025170331A (ja) メニン－ｍｌｌ相互作用の阻害剤
CN119486734A (zh) 癌症治疗中的egfr抑制剂
TW202517653A (zh) 治療自體免疫疾病之大環
JP2024545511A (ja) メニン－ｍｌｌ相互作用の阻害剤
WO2025175264A1 (en) Inhibitors of cdk2
HK40054699B (en) Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and use thereof
HK40009464B (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
HK1193089B (en) 6,5-heterocyclic propargylic alcohol compounds and uses therefor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination